RTGN · RetinalGenix Technologies Inc. · Executive Compensation
$3.99
At close · Sep 16
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$75.19M
Shares
18.84M
Volume · Sep 16
667
Avg daily vol (1 sessions)
667
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Cory Zwerling | Chief Financial Officer | Resigned | 2026-03-26 |
| Dessislava (Dessy) Boneva | director | Appointed | 2023-12-06 |
| Virender Ahluwalia | Interim Chief Financial Officer | Appointed | 2023-12-04 |
| Vinay Mehindru, MD, MBA | director of the Company | Appointed | 2022-07-28 |